Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases

Clinical Lung Cancer

Volumn 17, Issue 1, 2016, Pages 30-38.e1

  Tran, Thang N ^a   Selinger, Christina I ^a   Kohonen Corish, Maija R J ^b,c,d   McCaughan, Brian ^e   Kennedy, Catherine ^e   O'Toole, Sandra A ^a,b,f   Cooper, Wendy A ^a,c,f  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Suite 304   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biomarker; Fluorescent in situ hybridization; Hepatocyte growth factor receptor; Immunohistochemistry; Prognosis

Indexed keywords

SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LARGE CELL CARCINOMA; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE DOSAGE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84953355187     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.08.002     Document Type: Article

References (24)

1. E. Gherardi, W. Birchmeier, C. Birchmeier, and G. Vande Woude Targeting MET in cancer: rationale and progress Nat Rev Cancer 12 2012 89 103
2. C. Birchmeier, W. Birchmeier, E. Gherardi, and G.F. Vande Woude Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 2003 915 925
3. K. Okuda, H. Sasaki, H. Yukiue, M. Yano, and Y. Fujii Met gene copy number predicts the prognosis for completely resected non-small-cell lung cancer Cancer Sci 99 2008 2280 2285
4. L. Landi, G. Minuti, A. D'Incecco, and F. Cappuzzo Targeting c-MET in the battle against advanced non-small-cell lung cancer Curr Opin Oncol 25 2013 130 136
5. H. Koeppen, W. Yu, J. Zha, and et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib {+/-} onartuzumab in advanced non-small-cell lung cancer: MET expression levels are predictive of patient benefit Clin Cancer Res 20 2014 4488 4498
6. D. Spigel, J.E. Martin, O. Kenneth, and et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial (abstract 8000) J Clin Oncol 32 15 suppl 2014
7. R.D. Camidge, S.H. Ou, G. Shapiro, G.A. Otterson, and M.A. Socinski Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small-cell lung cancer (NSCLC) (abstract 8001) J Clin Oncol 32 15 suppl 2014
8. C.B. Han, J.T. Ma, F. Li, and et al. EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small-cell lung cancer and associated stage N2 lymph node-metastasis Cancer Lett 314 2012 63 72
9. World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart 2004 IARC Press Lyon, Oxford
10. American Joint Committee on Cancer AJCC Cancer Staging Manual 7th ed. 2010 Springer New York
11. C.I. Selinger, W.A. Cooper, S. Al-Sohaily, and et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer J Thorac Oncol 6 2011 1179 1189
12. T.N. Tran, C.I. Selinger, M.R. Kohonen-Corish, and et al. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small-cell lung cancer Lung Cancer 81 2013 462 467
13. M. Varella-Garcia Stratification of non-small-cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay Diagn Pathol 1 2006 19
14. H. Go, Y.K. Jeon, H.J. Park, S.W. Sung, J.W. Seo, and D.H. Chung High MET gene copy number leads to shorter survival in patients with non-small-cell lung cancer J Thorac Oncol 5 2010 305 313
15. S. Park, Y.L. Choi, C.O. Sung, and et al. High MET copy number and MET overexpression: poor outcome in non-small-cell lung cancer patients Histol Histopathol 27 2012 197 207
16. K. Tsuta, Y. Kozu, T. Mimae, and et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small-cell lung carcinomas J Thorac Oncol 7 2012 331 339
17. P. Jurmeister, D. Lenze, E. Berg, and et al. Parallel screening for ALK, MET and ROS1 alterations in non-small-cell lung cancer with implications for daily routine testing Lung Cancer 87 2015 122 129
18. F. Cappuzzo, A. Marchetti, M. Skokan, and et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients J Clin Oncol 27 2009 1667 1674
19. R. Dziadziuszko, M.W. Wynes, S. Singh, and et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small-cell lung cancer J Thorac Oncol 7 2012 340 347
20. Y.T. Chen, J.W. Chang, H.P. Liu, and et al. Clinical implications of high MET gene dosage in non-small-cell lung cancer patients without previous tyrosine kinase inhibitor treatment J Thorac Oncol 6 2011 2027 2035
21. H.U. Schildhaus, A.M. Schultheis, J. Rüschoff, and et al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung Clin Cancer Res 21 2015 907 915
22. L.V. Sequist, J. von Pawel, E.G. Garmey, and et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer J Clin Oncol 29 2011 3307 3315
23. M. Beau-Faller, A.M. Ruppert, A.C. Voegeli, and et al. MET gene copy number in non-small-cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort J Thorac Oncol 3 2008 331 339
24. D. Masuya, C. Huang, D. Liu, and et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients Br J Cancer 90 2004 1555 1562